Prof Meletios Dimopoulos talks to ecancer about DREAMM-8.

The study evaluated the efficacy and safety of BPd (belantamab mafodotin, pomalidomide, dexamethasone) compared to PVd (pomalidomide, bortezomib, dexamethasone) in patients with relapsed/refractory multiple myeloma (RRMM) who had received at least one prior therapy.

BPd significantly improved progression-free survival and showed a trend toward better overall survival compared to PVd.

BPd also resulted in deeper and more durable responses, though it was associated with a higher incidence of ocular adverse events.

Overall, BPd demonstrated a clinically meaningful progression-free survival benefit and manageable safety profile.